Compare · GILD vs XTNT
GILD vs XTNT
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Xtant Medical Holdings Inc. (XTNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and XTNT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 4110.4x XTNT ($44.9M).
- Over the past year, GILD is up 29.7% and XTNT is down 45.5% - GILD leads by 75.2 points.
- XTNT has been more active in the news (14 items in the past 4 weeks vs 12 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 1 for XTNT).
- Company
- Gilead Sciences Inc.
- Xtant Medical Holdings Inc.
- Price
- $148.78+1.33%
- $0.34-1.94%
- Market cap
- $184.47B
- $44.9M
- 1M return
- +13.98%
- -20.68%
- 1Y return
- +29.69%
- -45.52%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 1992
- News (4w)
- 12
- 14
- Recent ratings
- 25
- 1
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Xtant Medical Holdings Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest XTNT
- Director Lipschultz Tyler was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)
- Director Bakewell John K was granted 215,517 shares, increasing direct ownership by 24% to 1,129,633 units (SEC Form 4)
- Director Beeson Jonn R. was granted 215,517 shares, increasing direct ownership by 42% to 733,136 units (SEC Form 4)
- Director Jain Abhinav was granted 215,517 shares, increasing direct ownership by 136% to 373,745 units (SEC Form 4)
- Director Vizirgianakis Stavros G. was granted 323,275 shares, increasing direct ownership by 4% to 7,838,845 units (SEC Form 4)
- Chief Operating Officer Schallenberger Mark A. was granted 450,000 shares and covered exercise/tax liability with 7,070 shares, increasing direct ownership by 67% to 1,106,087 units (SEC Form 4) (withholding obligation)
- CFO and Assistant Secretary Neils Scott C was granted 400,000 shares and covered exercise/tax liability with 28,155 shares, increasing direct ownership by 44% to 1,215,226 units (SEC Form 4) (for withholding tax)
- President and CEO Browne Sean E was granted 550,000 shares and covered exercise/tax liability with 10,605 shares, increasing direct ownership by 21% to 3,114,669 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Xtant Medical Holdings Inc.
- Xtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits